Lantheus Surges on 414% Volume Spike Ranks 344th as Strategic Deals Drive Growth

On August 20, 2025, Lantheus Holdings (LNTH) rose 1.80% with a trading volume of $0.30 billion, marking a 414.5% increase from the previous day and ranking 344th in market activity. The stock’s performance coincided with several strategic developments.

The company announced the completion of its acquisition of Life Molecular Imaging, expanding its R&D capabilities under new leadership. Additionally, Lantheus sold its SPECT business to SHINE Technologies, a move aimed at refocusing resources on innovative radiopharmaceuticals. This transaction included the transfer of key products such as TechneLite® and NEUROLITE®.

Recent clinical progress highlighted the Alzheimer’s diagnostic tool MK-6240, which met co-primary endpoints in pivotal trials. Separately, the FDA accepted a new formulation of Lantheus’s PSMA PET imaging agent for review, signaling potential growth in nuclear medicine applications.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the past year, with a few fluctuations. As of the latest data, the strategy’s profit reached $2,385.14.